You are here: Industry Insights > ulcerative colitis

News List

Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals pharmatimes
July 20, 2018
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.
FDA approves Pfizer's Xeljanz for ulcerative colitis pharmatimes
July 11, 2018
The FDA has approved Pfizer's Xeljanz (tofacitinib) for the treatment of moderately to severely active ulcerative colitis.
FDA approves Pfizer's Xeljanz for ulcerative colitis pharmatimes
June 06, 2018
The FDA has approved Pfizer's Xeljanz (tofacitinib) for the treatment of moderately to severely active ulcerative colitis.
FDA Approves New Treatment for Ulcerative Colitis drugs
May 31, 2018
U.S. Food and Drug Administration approval of Xeljanz (tofacitinib) has been expanded to include adults with active moderate-to-severe ulcerative colitis, the agency said Wednesday.
Arena Pharmaceuticals Shares Explode on Positive Ulcerative Colitis Trial Data biospace
March 21, 2018
Arena Pharmaceuticals, Inc. shares rose 34 percent in premarket trading today after the company released positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.
First Wave Bio to Begin Clinical Trials of Novel Small-Molecule Therapy for Ulcerative Colitis biospace
January 31, 2018
First Wave Bio Inc., today announced that it has received regulatory approval to begin clinical testing of its lead product candidate (FW-424) for the treatment of ulcerative colitis (UC).
Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan pharmaceutical-technology
August 23, 2017
Takeda Pharmaceutical has filed a new drug application (NDA) for vedolizumab with Japan’s Ministry of Health, Labour and Welfare to treat adult patients with moderately to severely active ulcerative colitis (UC).
New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative en-cphi.cn
May 09, 2017
Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium
Arthritis Drug Shows Promise for Ulcerative Colitis drugs.com
May 04, 2017
A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.

Previous page 1 2 3 4 5 Next page